Exagen Inc.’s recent quarterly filing highlights a moderate revenue increase driven by 11% test volume growth and an improved average selling price for its core AVISE® CTD diagnostic product. The company is advancing clinical validation of new SLE and RA disease activity biomarkers, aimed at improving patient management. Exagen operates a CLIA-certified and CAP-accredited lab focused on autoimmune diseases, leveraging a specialized sales force to engage rheumatologists across 45 U.S. territories. Despite ongoing operating losses, Exagen benefits from laboratory infrastructure, proprietary biomarker panels, and strategic pharma partnerships that differentiate it in a reimbursement-challenged diagnostic market.